The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results